-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/quantitative-synthesis-expanded-methods_methods.pdf
March 01, 2013 - needs to be considered.
4
Combining Composite Outcomes
A composite outcome can be binary (0/ … control rate to rule out presence
of a control rate effect; if the slope is significantly different than 0, … A RD of 2 percent could
be clinically significant if the change is from 3 percent to 1 percent of an … Provide interpretation for results from test and exploration of heterogeneity. … Numbers
needed to treat derived from meta-analyses—
sometimes informative, usually misleading.
-
effectivehealthcare.ahrq.gov/sites/default/files/comparator-selection-in-observational-chapter-5.pptx
January 01, 2013 - Discuss potential bias (and methods to minimize it) associated with comparator choice
Define time 0 … Defining time 0 for all comparator groups in describing planned analyses is also important. … One issue with no-treatment comparison groups is how to identify time 0. … It also prevents bias from arising from prevalent users being long-term adherers who may also follow … Time from disease onset to a treatment:
Pay careful attention to the time from initial diagnosis and
-
effectivehealthcare.ahrq.gov/sites/default/files/considerations-for-statistical-chapter-10.pptx
January 01, 2013 - This presentation covers strategies for data analysis from simple descriptive statistics to more complex … Variables that are potentially on the pathway from treatment to outcome are not controlled for, because … Estimating causal effects from epidemiological data. … Like the propensity score, it is a summary measure derived from the observed values of the covariates … If subjects with missing data differ from subjects with complete data, then exposure estimates may be
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/ischemic-stroke-treatment_executive.pdf
January 01, 2011 - from
15 to 114 patients. … Penumbra System (numbers ranged
from 15 to 125 patients). … Mean/median time from stroke symptom to either
angiography or device deployment ranged from 141 to
388 … Consequently, the use of IV rtPA among studies ranged
from 0 to 100 percent. … 0 1 0 0
Patients 371 0 31 211 173 12 12 0 53 14 0 0 34 0 0
BI Studies 1 0 0 1 0 0
Patients 5 0 0
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-update-surv-rep-1-app-F1-4.xlsx
January 01, 2022 - C, Δ 95% CI Upper Limit Intervention D, N Analyzed for Mean Δ From Baseline Intervention D, Mean Δ From … 16 0 0 16 0 0 16 0 0 16 0 6 16 37.5 0 16 0 6 16 37.5 1 16 6.25 7 16 43.75 0 16 0 NR NR NR NR NR NR NR … 5 0 1 7 14.29 0 5 0 0 7 0 0 5 0 4 7 57.14 3 5 60 NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR … 34 0 0 32 0 2 34 5.88 0 32 0 18 34 52.94 5 32 15.63 3 34 8.824 2 32 6.25 3 34 8.82 0 32 0 NR NR NR NR … Placebo cream, max 4 applications/day NA NA 4 Short 0 15 0 0 14 0 0 15 0 0 14 0 NR NR NR NR NR NR NR
-
effectivehealthcare.ahrq.gov/news/best-of-2022
-
effectivehealthcare.ahrq.gov/sites/default/files/masks-surveillance-2-appendix-table-a-1.xlsx
April 09, 2020 - vs. 2% vs. 2%
1 adult influenza vaccinated: 0% vs. 4% vs. 4% A vs. … (0/92)
B: 0% (0/94)
C: 1% (1/100) Not reported Not reported A vs. … a randomly obtained swab from an asymptomatic participant; or influenza seroconversion (symptomatic … member (mean not reported)
A. 19% age 0-15; 20% age 16-30; 50% age 31-50; 11% age ≥51
B. 16% age 0-15 … vs. 0% vs. 0%
Household contacts
Vaccination at least 14 days prior to index case symptom onset: 3%
-
effectivehealthcare.ahrq.gov/sites/default/files/Masks-appendix-table-b-1-surveillance-report.xlsx
April 09, 2020 - vs. 2% vs. 2%
1 adult influenza vaccinated: 0% vs. 4% vs. 4% A vs. … (0/92)
B: 0% (0/94)
C: 1% (1/100) Not reported Not reported A vs. … a randomly obtained swab from an asymptomatic participant; or influenza seroconversion (symptomatic … member (mean not reported)
A. 19% age 0-15; 20% age 16-30; 50% age 31-50; 11% age ≥51
B. 16% age 0-15 … vs. 0% vs. 0%
Household contacts
Vaccination at least 14 days prior to index case symptom onset: 3%
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/women-hiv_disposition-comments.pdf
November 21, 2016 - Lives of Women Aged 40 and Above
Living With HIV/AIDS
Draft review available for public comment from … The findings from
the limited available literature were clearly stated. … We have expanded the Next Steps section with
input from this reviewer and others. … Upon closer examination
of the data it can be argued that forty-eight women
died from AIDS from 1980 … the social worker or if the text is the
interpretation/summary from the investigators.
-
effectivehealthcare.ahrq.gov/sites/default/files/masks-appendix-table-b-1-version-2.xlsx
April 09, 2020 - vs. 2% vs. 2%
1 adult influenza vaccinated: 0% vs. 4% vs. 4% A vs. … (0/92)
B: 0% (0/94)
C: 1% (1/100) Not reported Not reported A vs. … a randomly obtained swab from an asymptomatic participant; or influenza seroconversion (symptomatic … member (mean not reported)
A. 19% age 0-15; 20% age 16-30; 50% age 31-50; 11% age ≥51
B. 16% age 0-15 … vs. 0% vs. 0%
Household contacts
Vaccination at least 14 days prior to index case symptom onset: 3%
-
effectivehealthcare.ahrq.gov/products/febrile-infants-diagnosis-management/research
March 27, 2012 - 2011 Topic Initiated Mar. 27, 2012 Systematic Review Diagnosis and Management of Febrile Infants (0– … followup for return visits/reassessment of infants after initial examination across four studies ranged from
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-rept-1-acute-pain.xlsx
September 21, 2022 - B
Pain intensity (mean [99% CI] 0 to 10 NRS, estimated from figure): 4.2 (3.7 to 4.8) vs. 5.1 (4.5 to … B
Roland Morris Disability Questionnaire (mean [99% CI] 0 to 24, estimated from figure): 15 (14 to 16 … -1.7 to 0.0)
Pain improvement from baseline to 2 hours (mean [SD], 0 to 10 VAS): 4.0 (2.6) vs. 2.9 ( … B
Pain intensity (mean [SD NR], 0 to 10 VAS, estimated from figure): 2.6 vs. 3.2 at 4 hours, 3.1 vs. … C or D
Pain intensity difference (least mean square [SD NR], 0 to 10 NRS, estimated from graph): 5.2
-
effectivehealthcare.ahrq.gov/sites/default/files/ijzerman_ahrq-webinar-mcda.pdf
January 01, 2011 - AHP) CA methods
Adapted from Mulye et al, J. Beh.Dec. … in case of anti-depressants
15
How patients and experts value patient relevant endpoints
0
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-tables-f1-f2-2022-update_0.xlsx
January 01, 2022 - Table F-1. ROB RCTs
Table F-1. Risk of bias of cannabis RCTs
Author, Year Randomization Adequate? Allocation Concealment Adequate? Groups Similar at Baseline? Patient Masked? Care Provider Masked? Outcome Assessors Masked? Intention-To-Treat Analysis? Rate of Overall Attrition Within Acceptable Levels? Rate of Diffe…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/recombinant-factor-viia_executive.pdf
May 01, 2010 - These uses
differ substantially from the drug’s FDA
approved label. … 08
-0
.2
2
0.
04
-0
.1
1
0.
44
-0
.5
3
4-
79
ex
pa
ns
io
n
U
C
:
U
C
:
U
C
:
U
C
:
In … 07
-0
.3
1
0.
03
-0
.1
2
0.
02
-0
.0
6
6.
9-
16
.0
•
H
ad
a
n
un
cl
ea
r
im
pa
ct … 0.
51
0-
0.
08
0.
04
-0
.1
6
7.
7-
14
.0
po
te
nt
ia
l f
or
b
en
ef
it
an
d
lit
tle … U
C
:
U
C
:
U
C
:
0.
11
-0
.5
3
0.
08
-0
.1
8
10
.4
K
Q
4
a
.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-tables-E-1-E-4.xlsx
January 01, 2023 - graph) NR NR NR 6 -0.2 (estimated from graph) NR NR NR 10 0 (estimated from graph) NR NR NR NA NA NA … 16 0 0 16 0 NA NA NA NA NA NA 0 16 0 0 16 0 NA NA NA NA NA NA 6 16 37.5 0 16 0 NA NA NA NA NA NA 6 16 … 5 0 NA NA NA NA NA NA 1 7 14.29 0 5 0 NA NA NA NA NA NA 0 7 0 0 5 0 NA NA NA NA NA NA 4 7 57.14 3 5 60 … Placebo cream, max 4 applications/day NA NA 4 Short 0 15 0 0 14 0 NA NA NA NA NA NA 0 15 0 0 14 0 NA … Placebo 8 Short NR NR NR NR NR NR NR NR NR NR NR NR 0 28 0 0 27 0 1 30 3.33 0 30 0 1 28 3.57 2 27 7.41
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/quality-rating_research.pdf
November 01, 2011 - Proportions of disagreements ranged from 0 percent (unanimous agreement among the
reviewers in all studies … 0%
0%
9%
64%
55%
45%
0%
18%
27%
27%
9%
27%
18%
0%
27%
45%
0%
18%
0% 20% 40% 60% 80% … 0%
0%
46%
69%
8%
0%
0%
0%
92%
69%
69%
38%
100%
85%
100%
5%
10%
95%
65%
45%
0%
20% … 36%
9%
73%
0%
0%
9%
9%
9%
0%
18%
0%
27%
18%
45%
0%
9%
0%
73%
27%
0%
27%
0%
73% … Disagreements among reviewers ranged from 0 to 100
percent, indicating variable subjectivity across
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/restless-legs_research-protocol.pdf
December 16, 2011 - severity of
disease and its impact
Scale with 10 items with each
item rated on a 5 point scale (0 … symptoms)
Scores are combined to give a
global assessment (0: No RLS;
1-10: mild; 11-20: moderate … Severity Rating
Scale
ASRS, developed by the
European RLS Study Group
A total score (range 0 … to 24) is
3 items (9 point: 0 = no sign of
augmentation, 8 = signs of
severe augmentation) are … will set
responder criteria on these scale scores to be: 1) resolution of symptoms (IRLS scale score=0)
-
effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/ems-911-workforce-topic-development-brief.pdf
February 01, 2022 - -94
Total number of identified systematic reviews: 0
• AHRQ EPC: 0
• Cochrane: 0
• VA ESP: 0
• … PubMed: 0
• PsycInfo: 0
Primary articles: 0
1b and 2:
Interventions
addressing
behavioral health … • Recruiting: 0
• Active: 0
• Complete: 0
Total number of identified systematic reviews: 1
• AHRQ … EPC: 0
• Cochrane: 0
• VA ESP: 0
• PubMed: 115
• PsycInfo: 0
Primary articles: 10136-145 … Clinicaltrials.gov
• Recruiting: 0
• Active: 0
• Complete: 0
AHRQ=Agency for Healthcare Research
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-3-immunity-after-COVID-19-appendix-table-B-1.xlsx
January 24, 2022 - Mild:
Asthma/seasonal allergies: 6 (31.6)
Diabetes: 2 (10.5)
Hypertension: 5 (26.3)
Cardiovascular: 0( … Caucasian: 31 (88.6)
African: 3 (8.6)
Asian: 1 (2.9)
Immunocompetent
Caucasian: 34 (97.1)
African: 0 … (0)
CVD: 4* (7.5)
Asthma:4* (5.7)
CKD stage 4 or 5: 0 (0) Anti-S RBD Architect SARS-CoV-2 IgG Quant Antibody … infection
0-7 days
10-28 days
6 to 10 weeks
6 to 12 months From participants included for serological … SARS-CoV-2 infection were collected from the SmiNet register.